Preferred Name |
Cilazapril Anhydrous |
|
Synonyms |
|
|
Definitions |
The anhydrous form of the pyridazine angiotensin-converting enzyme (ACE) inhibitor cilazapril with antihypertensive activity. As a prodrug cilazapril is rapidly metabolized in the liver to cilazaprilat; cilazaprilat competitively binds to and inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the potent vasoconstrictive actions of angiotensin II, resulting in vasodilation. Cilazaprilat also decreases angiotensin II-induced aldosterone secretion by the adrenal cortex, which leads to an increase in sodium excretion and subsequently increases water outflow. |
|
ID |
http://purl.obolibrary.org/obo/NCIT_C76134 |
|
CAS_Registry |
88768-40-5 |
|
Chemical_Formula |
C22H31N3O5 |
|
code |
C76134 |
|
Contributing_Source |
FDA |
|
definition |
The anhydrous form of the pyridazine angiotensin-converting enzyme (ACE) inhibitor cilazapril with antihypertensive activity. As a prodrug cilazapril is rapidly metabolized in the liver to cilazaprilat; cilazaprilat competitively binds to and inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the potent vasoconstrictive actions of angiotensin II, resulting in vasodilation. Cilazaprilat also decreases angiotensin II-induced aldosterone secretion by the adrenal cortex, which leads to an increase in sodium excretion and subsequently increases water outflow. |
|
FDA_UNII_Code |
8Q9454114Q |
|
in_subset | ||
label |
Cilazapril Anhydrous |
|
Legacy Concept Name |
Cilazapril_Anhydrous |
|
Preferred_Name |
Cilazapril Anhydrous |
|
prefixIRI |
NCIT:C76134 |
|
prefLabel |
Cilazapril Anhydrous |
|
Semantic_Type |
Pharmacologic Substance |
|
UMLS_CUI |
C0886706 |
|
subClassOf |
Delete | Mapping To | Ontology | Source |
---|---|---|---|
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C76134 | NCIT | LOOM | |
http://purl.bioontology.org/ontology/SNOMEDCT/1268982005 | SNOMEDCT | LOOM |